ITRI has developed a novel coordinated supramolecular composite carrier technology for efficient drug delivery to the posterior eyeball in eye drop products. Using this technology, ITRI has successfully developed the world's most convenient eye drop treatment for wet AMD, replacing the need for ocular injections. The product addresses needle phobia and reduces risks of bleeding and infection associated with injections, offering a non-invasive and self-administrable solution.

Features & Specifications:
．Substaintial enhancement of drug solubility and ocular tissue penetration
．Non-invasive drug delivery technology for posterior ocular drug delivery
．Substitution of eye Injections with the eye drop products